Improved Diagnostic and Prognostic Tools for Rheumatoid Arthritis: Unmet Needs in a Changing MarketDecision ResourcesMarch 21, 2005 19 Pages - SKU: DECR1186941 |
| According to recent clinical studies, the key to achieving optimal outcomes in rheumatoid arthritis (RA) is to diagnose and treat it as early as possible. The need to develop more-sensitive and more-specific markers for early-stage disease is urgent. While developments in disease- modifying drugs and biologic agents have revolutionized the treatment of RA, enabling physicians to slow disease progression and prevent some joint destruction, diagnostics has lagged behind. Therefore, the challenge in this area of medicine lies almost exclusively in the diagnosis of early-stage RA, which can be accomplished only with novel serological tests, imaging techniques, or RA biomarkers. This report profiles the efforts under way by a variety of companies in this area of great unmet need.
Please note, the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
Rheumatology/Arthritis Reports
- China Rheumatoid Arthritis Prescription Drug Sales Data 2006-2010
- Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market
- Rheumatoid Arthritis Market Forecast
- Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis - Novel therapies plus reformulations poised to enter the market
